BPC-157/ Thymosin B4 ( (Ac-SDKP) Research Formulation

Dual-Action Peptide Combination for Regenerative Pathway Investigation

This formulation provides a combination of two structurally distinct peptides for concurrent evaluation in advanced laboratory settings: Body Protection Compound-157 (BPC-157) and the Thymosin Beta-4 fragment (Ac-SDKP). The peptides are co-formulated in an oral capsule, leveraging a stable BPC-157 arginate salt and Salcaprozate Sodium (SNAC) as an absorption enhancer to facilitate systemic delivery in experimental models.

Peptide Research Profile: BPC-157

BPC-157 is a synthetic pentadecapeptide that is a subject of extensive preclinical investigation into pleiotropic tissue regeneration and cellular defense mechanisms.

• Molecular Mechanism: Preclinical studies indicate BPC-157 coordinates angiogenesis by upregulating vascular endothelial growth factor receptor 2 (VEGFR2) and activating the Akt-eNOS pathway. This activity supports endothelial cell migration and collateral blood vessel growth research.
• Cytoprotective Studies: The compound is studied for its ability to stabilize mucosal permeability and tight junctions in gastrointestinal models, offering a substrate for research into protection against induced cytotoxicity and lesion formation.
• Tissue Remodeling: Investigational models show BPC-157 accelerates the process of collagen reorganization and promotes the formation of granulation tissue in soft tissue and musculoskeletal injury models.

Peptide Research Profile: Ac-SDKP (Goralatide)

Ac-SDKP, historically referred to as Goralatide, is the bioactive N-terminal tetrapeptide of Thymosin Beta-4. It is primarily characterized as a potent anti-fibrotic agent and cell cycle regulator in research settings.

• Anti-Fibrotic Signaling: Research focuses on its mechanism of inhibiting the differentiation of fibroblasts into active myofibroblasts, which can prevent excessive collagen deposition and subsequent fibrosis in various somatic tissue models.
• Hematopoietic Studies: It functions as a physiological regulator studied for its ability to selectively restrict active hematopoietic stem and progenitor cells, arresting them in the quiescent G0 state.

Synergistic Research Pathways

The combination is investigated for complementary effects, pairing BPC-157’s initiation of angiogenesis and cell migration with Ac-SDKP’s regulation of the tissue remodeling phase and anti-scarring action. Potential research pathways include:

• Soft Tissue Repair: Evaluation of combined mechanisms for improving the formation of functional tissue structure, particularly in tendon-ligament complexes and musculoskeletal research.
• Cardiovascular Remodeling: Investigation into limiting pathological remodeling following tissue ischemia by coordinating improved microvascular blood flow (BPC-157) and reducing myofibroblast activation (Ac-SDKP).

Clinical Study Summary (External References)

Details regarding approved human studies or clinical trials involving BPC-157/ Thymosin B4 (Ac-SDKP) analogs for reference:

• A Phase I/II randomized, double-blind, placebo-controlled trial (NCT07437547) is currently recruiting participants to evaluate the efficacy of daily subcutaneous BPC-157 injections in patients with acute, MRI-confirmed Grade II hamstring strains .
• Safety and tolerability of a BPC-157 rectal enema formulation (PL-14736) were confirmed in a Phase II multicenter, randomized, double-blind, placebo-controlled trial for mild-to-moderate ulcerative colitis, though clinical development was halted .
• Clinical trials evaluating Ac-SDKP (Goralatide) in cancer patients undergoing cytotoxic monochemotherapy demonstrated that pre-treatment successfully restricted bone marrow stem cells to the quiescent G0 phase, leading to accelerated neutrophil recovery and reduced bone marrow damage .
• An analog of the full-length peptide (RGN-259) achieved complete corneal healing in 6/10 treated subjects in the randomized, double-masked, placebo-controlled Phase III SEER-1 trial for Stages 2 and 3 Neurotrophic Keratopathy .

Product Specifications

• Product Name: BPC-157 / Thymosin β4 (Ac-SDKP)
• Active Ingredients: BPC-157 500 mcg; Thymosin B4 (Ac-SDKP) 2.5mg
• Count: 60 capsules
• SKU: BPTB-CAP-102.5MG
• Brand: Simple Peptide

---

Disclaimer: This product is sold strictly for laboratory research and educational reference. It is not approved by the U.S. Food and Drug Administration (FDA) for human consumption, a dietary supplement, drug, or medical device. By purchasing this material, the Buyer acknowledges that they will use it solely in accordance with applicable laws and regulations and accept full responsibility for its use.